On February 16, 2023 Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, reported its fourth quarter 2022 results (Press release, Targovax, FEB 16, 2023, View Source [SID1234627320]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Members of Targovax’s executive management team will give an online presentation to investors, analysts and the press at 10:00 CET today (details below).
FOURTH QUARTER 2022 HIGHLIGHTS
ONCOS-102
The phase 1b melanoma study was selected for oral presentation at the prestigious Society for Immunotherapy in Cancer (SITC) (Free SITC Whitepaper) annual meeting
The phase 1b melanoma full study results were published in the high-impact oncology journal Clinical Cancer Research
CircRNA pipeline program
Key technical proof-of-concept data were established, and IP filed for the in-house circRNA design and circAde vector
Mutant KRAS platform
The TG01 trial in multiple myeloma at Oslo University Hospital received regulatory approvals to proceed
A clinical trial collaboration was announced with Agenus and Kansas University to test TG01 in combination with PD1 checkpoint inhibitor balstilimab in pancreatic cancer
Corporate
Hubro Therapeutics acquired GM-CSF vaccine adjuvant for NOK 10m from Targovax ASA in an asset purchase agreement
POST-PERIOD HIGHLIGHTS
In February 2023, Targovax announced financing of up to NOK 300m over three years to advance its clinical cancer programs & pre-clinical circular RNA platform
Erik Digman Wiklund, CEO commented: "We are now well positioned to execute on all our R&D programs in 2023. During the year, we expect both ONCOS-102 and TG01 to progress rapidly in clinical studies at major cancer centers in the USA and Europe, teeing up important read-outs in 2024. For circRNA, we aim to establish in vivo proof-of-concept in several settings, and firmly establish Targovax as the leader in vector-delivered circRNA therapeutics – aiming to be first into the clinic with a circRNA product for cancer treatment already in 2025. To further strengthen our financial position, we are building on the momentum in the RNA field to actively pursue additional opportunities to help unlock the substantial potential value of our circRNA platform"
Key figures
Amounts in NOK thousands 4Q 2022 4Q 2021 FY 2022 FY 2021
Total operating revenues 10 002 – 10 002 –
Total operating expenses -32 198 -25 523 -112 266 -95 601
Operating profit/loss -22 196 -25 523 -102 264 -95 601
Net financial items -17 -1 129 -313 -2 422
Income tax
9 10 40 52
Net profit/loss -22 204 -26 641 -102 537 -97 971
Basic and diluted EPS (NOK/share) -0.12 -0.28 -0.54 -1.10
Net change in cash -30 171 127 617 -115 667 59 360
Cash and cash equivalents start of period 96 186 54 064 181 682 122 321
Cash and cash equivalents end of period 66 015 181 682 66 015 181 682
The interim financial information has not been subject to audit
Presentation
We invite to a live webcast today at 10.00 CET. You can join the webcast here. It will be possible to submit questions during the presentation.
Reporting material
TRVX 4Q’22 report.pdf
TRVX 4Q’22 presentation.pdf
The quarterly report and presentation are also available at the website www.targovax.com.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: [email protected]
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: [email protected]
Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: [email protected]